|
|
News Breaks
|
November 19, 2009
|
| 07:39 EDT |  | GERN |
| theflyonthewall.com: | Geron presents data on AACR-NCI-EORTC | | Geron announced the presentation of interim data from its ongoing trial of imetelstat, a telomerase inhibitor drug, in patients with refractory, advanced solid cancers at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. “I am pleased to report that we have met our Phase I objectives for imetelstat and can advance the program,” said Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., Geron’s executive vice president and chief medical officer, oncology. “As the data from the study in patients with solid tumors presented today illustrates, we are achieving exposures to imetelstat that exceed the levels that have been associated with efficacy in several models of human cancers and we are also observing telomerase inhibition in tissue samples from patients, while minimizing hematological toxicities through an alternative dosing schedule. In 2010 we plan to initiate four Phase II clinical trials of imetelstat in multiple cancers.” :theflyonthewall.com |
|
|
News For GERN From The Last 14 Days Check below for free stories on GERN the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 23, 2012
|
| 13:50 EDT |  | GERN |
|
|
|
|
|
Subscribe for More Information